Nuvation Bio Reports Positive Phase 2 Study Results

Nuvation Bio ( (NUVB) ) has provided an update.

On November 8, 2025, Nuvation Bio announced positive results from a Phase 2 study of safusidenib in Japanese patients with IDH1-mutant gliomas, showing a 44.4% objective response rate and long-term potential to delay disease progression. The study highlighted the drug’s promising efficacy and manageable adverse events, despite a Good Clinical Practice noncompliance issue related to safety reporting. The company is advancing the G203 study to a global Phase 3 trial to support potential regulatory approvals, aiming to expand its market positioning in high-grade IDH1-mutant gliomas.

The most recent analyst rating on (NUVB) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Nuvation Bio stock, see the NUVB Stock Forecast page.

Spark’s Take on NUVB Stock

According to Spark, TipRanks’ AI Analyst, NUVB is a Neutral.

Nuvation Bio’s stock is primarily challenged by weak financial performance, characterized by ongoing losses and negative cash flows, despite a strong equity foundation. While there is short-term momentum in the stock price, the lack of sustainable income and negative valuation metrics, such as a negative P/E ratio, weigh heavily on the overall score. The stock’s speculative nature and reliance on future growth prospects contribute to its moderate overall score.

To see Spark’s full report on NUVB stock, click here.

More about Nuvation Bio

Nuvation Bio is a global, commercial-stage oncology company focused on innovating and developing first- or best-in-class medicines for diseases with large unmet patient needs. The company is involved in developing treatments such as IBTROZI, a ROS1 inhibitor for advanced ROS1+ NSCLC, and safusidenib, a brain-penetrant inhibitor for IDH1-mutant gliomas.

Average Trading Volume: 7,552,575

Technical Sentiment Signal: Buy

Current Market Cap: $1.67B

For a thorough assessment of NUVB stock, go to TipRanks’ Stock Analysis page.